| Pazopanib | sarcoma, in NMA | vs placebo | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | relapse | no data | | progression or death (progression free survival PFS) | no data | | Adverse events leading to treatment discontinuation | no data | | objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | Grade 3–5 drug-related AEs | no data | | serious drug-related adverse events | no data | | recurrence free survival | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | distant metastasis free survival | no data | | aaa | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| PALETTE (van der Graaf), 2012 | | | |
|
| Ipilimumab | melanoma, in adjuvant stage III only - NOVARTIS | vs placebo | by 28% | - | by 24% | - | - | by 107% | by 107% | - | by 24% | - | - | - | by 24% | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.72 [0.58 0.89] | p=0.04 | 0 | 951 | 1 | EORTC 18071 (Eggermont), | | relapse | no data | | progression or death (progression free survival PFS) | 0.76 [0.64 0.90] | p=0.04 | 0 | 951 | 1 | EORTC 18071 (Eggermont), | | Adverse events leading to treatment discontinuation | no data | | objective response (ORR) | no data | | Grade 3–5 drug-related AEs | 2.07 [1.57 2.72] | p=0.04 | 0 | 945 | 1 | EORTC 18071 (Eggermont), | | Grade 3–5 drug-related AEs | 2.07 [1.57 2.72] | p=0.04 | 0 | 945 | 1 | EORTC 18071 (Eggermont), | | serious drug-related adverse events | no data | | recurrence free survival | 0.76 [0.64 0.90] | p=0.04 | 0 | 951 | 1 | EORTC 18071 (Eggermont), | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | distant metastasis free survival | 0.76 [0.63 0.91] | p=0.04 | 0 | 951 | 1 | EORTC 18071 (Eggermont), | | aaa | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| EORTC 18071 (Eggermont), 2015 | ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses, then every 3 months for up to 3 years or until disease recurrence or an unacceptable level of toxic effects occurred | placebo | high risk patients who had undergone complete resection of stage III melanoma |
|
| Nivolumab | melanoma, in adjuvant stage III only - NOVARTIS | vs ipilimumab | - | - | by 35% | - | - | - | - | - | by 35% | - | - | - | by 27% | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | relapse | no data | | progression or death (progression free survival PFS) | 0.65 [0.51 0.82] | p=0.04 | 0 | -18 | 1 | CheckMate 238 subgroup IIIB-C, | | Adverse events leading to treatment discontinuation | no data | | objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | Grade 3–5 drug-related AEs | no data | | serious drug-related adverse events | no data | | recurrence free survival | 0.65 [0.51 0.82] | p=0.04 | 0 | -18 | 1 | CheckMate 238 subgroup IIIB-C, | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | distant metastasis free survival | 0.73 [0.56 0.96] | p=0.04 | 0 | -18 | 1 | CheckMate 238 subgroup IIIB-C, | | aaa | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CheckMate 238 subgroup IIIB-C, | | | |
|
| Pembrolizumab | melanoma, in adjuvant stage III only - NOVARTIS | vs placebo | - | - | by 43% | - | - | by 335% | by 335% | - | by 43% | - | by 196% | NS | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | relapse | no data | | progression or death (progression free survival PFS) | 0.57 [0.43 0.75] | p=0.04 | 0 | 1019 | 1 | KEYNOTE-054, | | Adverse events leading to treatment discontinuation | no data | | objective response (ORR) | no data | | Grade 3–5 drug-related AEs | 4.35 [2.53 7.48] | p=0.04 | 0 | 1011 | 1 | KEYNOTE-054, | | Grade 3–5 drug-related AEs | 4.35 [2.53 7.48] | p=0.04 | 0 | 1011 | 1 | KEYNOTE-054, | | serious drug-related adverse events | no data | | recurrence free survival | 0.57 [0.43 0.75] | p=0.04 | 0 | 1019 | 1 | KEYNOTE-054, | | toxic death | no data | | vitiligo any grade | 2.96 [1.32 6.65] | p=0.04 | 0 | 1011 | 1 | KEYNOTE-054, | | vitiligo grade 3-4 | 0.99 [0.02 49.80] | p=1.00 | 0 | 1011 | 1 | KEYNOTE-054, | | distant metastasis free survival | no data | | aaa | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| KEYNOTE-054, 2018 | Pembrolizumab (Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 1 year)
| placebo | patients with complete Resection of High-Risk Stage III Melanoma |
|
| Vemurafenib | melanoma, in adjuvant stage III only - NOVARTIS | vs placebo | - | - | NS | - | - | - | - | - | NS | - | - | - | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | relapse | no data | | progression or death (progression free survival PFS) | 0.80 [0.54 1.18] | p=1.00 | 0 | -18 | 1 | BRIM 8 (cohort IIIC), | | Adverse events leading to treatment discontinuation | no data | | objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | Grade 3–5 drug-related AEs | no data | | serious drug-related adverse events | no data | | recurrence free survival | 0.80 [0.54 1.18] | p=1.00 | 0 | -18 | 1 | BRIM 8 (cohort IIIC), | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | distant metastasis free survival | 0.91 [0.57 1.45] | p=1.00 | 0 | -18 | 1 | BRIM 8 (cohort IIIC), | | aaa | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| BRIM 8 (cohort IIIC), | | | |
|
| Trametinib + dabrafenib | melanoma, in adjuvant stage III only - NOVARTIS | vs placebo | by 43% | - | by 53% | - | - | - | - | - | - | - | - | - | - | by 49% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.57 [0.42 0.78] | p=0.04 | 0 | -18 | 1 | COMBI-AD, | | relapse | no data | | progression or death (progression free survival PFS) | 0.47 [0.39 0.57] | p=0.04 | 0 | -18 | 1 | COMBI-AD, | | Adverse events leading to treatment discontinuation | no data | | objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | Grade 3–5 drug-related AEs | no data | | serious drug-related adverse events | no data | | recurrence free survival | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | distant metastasis free survival | no data | | aaa | 0.51 [0.40 0.65] | p=0.04 | 0 | -18 | 1 | COMBI-AD, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| COMBI-AD, 2017 | dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months | placebo | Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk [Stage IIIa (lymph node metastasis >1 mm), IIIb or IIIc] cutaneous melanoma |
|
| Interferon alpha | melanoma, in adjuvant stage III only - NOVARTIS | vs observation | NS | - | by 13% | - | - | - | - | - | - | - | - | - | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 1.01 [0.87 1.16] | p=1.00 | 0 | -36 | 2 | EORTC18991 (Eggermont), EORTC18871/DKG 80-1 stage III, | | relapse | no data | | progression or death (progression free survival PFS) | 0.87 [0.76 1.00] | p=0.04 | 0 | -18 | 1 | EORTC18991 (Eggermont), | | Adverse events leading to treatment discontinuation | no data | | objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | Grade 3–5 drug-related AEs | no data | | serious drug-related adverse events | no data | | recurrence free survival | no data | | toxic death | no data | | vitiligo any grade | no data | | vitiligo grade 3-4 | no data | | distant metastasis free survival | 0.93 [0.81 1.07] | p=1.00 | 0 | -18 | 1 | EORTC18991 (Eggermont), | | aaa | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| EORTC18991 (Eggermont), 2008 | pegylated interferon alfa-2b 6 mug/kg per week for 8 weeks (induction) then 3 mug/kg per week (maintenance) for an intended duration of 5 years | | patients with resected stage III melanoma | | EORTC18871/DKG 80-1 stage III, | | | |
|
